Certara, Inc. (CERT)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 11.35 (gtc) on the pullback to the tested 11.29 support — structure-based stop 10.75, targets 12.55 / 13.45, R/R 2.00 on a 1–15 day hold. The breakout alternative was evaluated and rejected: a buy-stop over the settled 12.61 52-week high gives R/R 0.81 (< 1.0 floor) against the same 11.29 swingLow, so the retest is the only economically honest entry. All gates passed: $11.90 ≤ $25, fundamentalScore 3, qualitativeScore 3, avgDollarVolume20 $30.49M, recent 3-session $32.44M, max overnight gap 1.76%, no in-window earnings or material dividend, ATR 5.04% of price, and the limit is trend-aligned (price ≥ SMA50, MACD > 0, price > SMA200).
Company overview
Certara, Inc. provides software solutions and services focused on biosimulation across the drug development lifecycle. The company aids in drug discovery, clinical trials, regulatory submissions, and market entry with its biosimulation software and expertise. Its clients include biopharmaceutical firms, academic institutions, and government organizations.
Fundamental
fairCertara's fundamentals are mixed, with strong cash flow but decelerating growth and negative GAAP margins due to accounting factors.
Cash-rich but GAAP-unprofitable: Certara generates solid free cash flow, carries under 1x net leverage and has no near-term debt maturities, yet revenue growth has decelerated to a guided 2%-3% for 2026, trailing GAAP margins remain negative because of acquired-intangible amortization and a $40.7M after-tax divestiture loss, and both discounted-cash-flow models plus the analyst consensus price target sit below the current share price.
Sentiment
fairSentiment is mildly positive, with recent earnings beats but tempered by narrowed growth guidance.
Q3 2026 results (2026-11-05, announced) are the dominant catalyst and the market rewarded them — adjusted EPS and revenue beat, software grew 11% organically, adjusted EBITDA margin expanded ~3.7pp q/q and the stock printed a 52-week high at $12.00 — but the print is eight days old, only partially priced, and tempered by services revenue −2%, a wider GAAP net loss and full-year revenue growth guidance narrowed to 2%–3%, so it does not clear the rewarded-and-still-actionable bar for the top band (trailing-catalyst ceiling applied). Media polarity is mildly positive (+0.24 across nine scored items) against a degraded single-item baseline (+0.30) for a flat delta, the Red-Flag Screen is clean with no severe or moderate flag, and retail is indeterminate (Reddit access blocked).
Technical
goodTechnicals show a continuation pattern with a recent breakout and consolidation above key moving averages.
The chart is a clean post-earnings continuation structure: an 8.65% earnings gap on 2026-11-05 took price from a 10.82 low to a 12.18 close, extended to a 12.61 52-week high on 2026-11-06, and the stock has since digested that move inside a tight 11.29–12.61 range while holding above the SMA20 (10.97), SMA50 (9.63), SMA200 (7.35), EMA9 (11.68) and EMA21 (11.03). Momentum confirms the direction of the trend rather than fighting it — RSI14 65.31, Williams %R -28.06, MACD line 0.70 above signal 0.66 — though the MACD histogram has decayed from +0.12 to +0.04 and ADX has eased from 54.20 to 52.89, which is why the score is 4 rather than 5. The 2026-11-12 session is the tell: a dip to 11.29 was bought aggressively and the session closed at 11.90 near its high, so 11.29 is the swing low the trade is built around. A breakout buy-stop over the 12.61 high cannot pay: with the stop under 11.29 the risk is 1.48 against a 1.20 first-target distance (R/R 0.81 < 1.0), so the only economically honest expression is to buy the retest. A limit at 11.35 sits just above that tested low; the structural stop (11.29 − buffer 0.12 = 11.17) is floored by the Change-A pullback rule to 10.75, which is 1.0 × ATR14 below entry and also below the EMA21 (11.03) and the 2026-11-05 gap low (10.82), so it protects the structure rather than the entry. Targets 12.55 and 13.45 bracket the prior high and a measured continuation, giving R/R 2.00 on a 1–15 day horizon. All gates cleared: $11.90 ≤ $25, fundamentalScore 3 and qualitativeScore 3, avgDollarVolume20 $30.49M, recent 3-session $32.44M, no overnight gap above 5% (max 1.76%), no in-window earnings or material dividend, ATR 5.04% of price, and a trend-aligned (not countertrend) limit.
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

